Accordingly, Revacept, a competitive antagonist of GPVI, was applied to patients with high-grade symptomatic ICA stenosis in a recent phase 2 trial to prevent recurrent stroke, but only a combined endpoint of neurological and cardiological events and death reached statistical significance [16]. Here, GP6 is linked to Stroke.